Ayala, R., Fernández, R. A., García-Gutiérrez, V., Alvarez-Larrán, A., Osorio, S., Sánchez-Pina, J. M., . . . Martinez-Lopez, J. (2023). Janus kinase inhibitor ruxolitinib in combination with nilotinib and prednisone in patients with myelofibrosis (RuNiC study): A phase Ib, multicenter study.
Citación estilo ChicagoAyala, Rosa, et al. Janus Kinase Inhibitor Ruxolitinib in Combination With Nilotinib and Prednisone in Patients With Myelofibrosis (RuNiC Study): A Phase Ib, Multicenter Study. 2023.
Cita MLAAyala, Rosa, et al. Janus Kinase Inhibitor Ruxolitinib in Combination With Nilotinib and Prednisone in Patients With Myelofibrosis (RuNiC Study): A Phase Ib, Multicenter Study. 2023.
Precaución: Estas citas no son 100% exactas.